<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Kidney J</journal-id><journal-id journal-id-type="iso-abbrev">Clin Kidney J</journal-id><journal-id journal-id-type="pmc-domain-id">1780</journal-id><journal-id journal-id-type="pmc-domain">ckj</journal-id><journal-id journal-id-type="publisher-id">ckj</journal-id><journal-title-group><journal-title>Clinical Kidney Journal</journal-title></journal-title-group><issn pub-type="ppub">2048-8505</issn><issn pub-type="epub">2048-8513</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11270017</article-id><article-id pub-id-type="pmcid-ver">PMC11270017.1</article-id><article-id pub-id-type="pmcaid">11270017</article-id><article-id pub-id-type="pmcaiid">11270017</article-id><article-id pub-id-type="pmid">39056070</article-id><article-id pub-id-type="doi">10.1093/ckj/sfae164</article-id><article-id pub-id-type="publisher-id">sfae164</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00340</subject></subj-group></article-categories><title-group><article-title>Effects of ACE inhibitor/ARB therapy and long COVID on kidney disease: a retrospective cohort study using real-world data</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6875-0025</contrib-id><name name-style="western"><surname>Zhang</surname><given-names initials="Y">Yue</given-names></name><aff>
<institution>Department of Public Health Sciences, Penn State College of Medicine</institution>, <addr-line>Hershey, PA</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ba</surname><given-names initials="DM">Djibril M</given-names></name><aff>
<institution>Department of Public Health Sciences, Penn State College of Medicine</institution>, <addr-line>Hershey, PA</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Risher</surname><given-names initials="K">Kathryn</given-names></name><aff>
<institution>Department of Public Health Sciences, Penn State College of Medicine</institution>, <addr-line>Hershey, PA</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liao</surname><given-names initials="D">Duanping</given-names></name><aff>
<institution>Department of Public Health Sciences, Penn State College of Medicine</institution>, <addr-line>Hershey, PA</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Parent</surname><given-names initials="LJ">Leslie J</given-names></name><aff>
<institution>Department of Public Health Sciences, Penn State College of Medicine</institution>, <addr-line>Hershey, PA</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Department of Medicine, Penn State College of Medicine</institution>, <addr-line>Hershey, PA</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0299-9394</contrib-id><name name-style="western"><surname>Ghahramani</surname><given-names initials="N">Nasrollah</given-names></name><aff>
<institution>Department of Public Health Sciences, Penn State College of Medicine</institution>, <addr-line>Hershey, PA</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Department of Medicine, Penn State College of Medicine</institution>, <addr-line>Hershey, PA</addr-line>, <country country="US">USA</country></aff><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chinchilli</surname><given-names initials="VM">Vernon M</given-names></name><aff>
<institution>Department of Public Health Sciences, Penn State College of Medicine</institution>, <addr-line>Hershey, PA</addr-line>, <country country="US">USA</country></aff></contrib></contrib-group><author-notes><corresp id="cor1">Correspondence to: Nasrollah Ghahramani; E-mail: <email>nghahramani@pennstatehealth.psu.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>7</month><year>2024</year></pub-date><pub-date pub-type="epub" iso-8601-date="2024-06-08"><day>08</day><month>6</month><year>2024</year></pub-date><volume>17</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">465902</issue-id><elocation-id>sfae164</elocation-id><history><date date-type="received"><day>26</day><month>2</month><year>2024</year></date><date date-type="corrected-typeset"><day>25</day><month>7</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>06</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>25</day><month>07</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-07-26 17:25:17.157"><day>26</day><month>07</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="sfae164.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sfae164.pdf"/><abstract><title>ABSTRACT</title><sec id="abs1"><title>Background</title><p>The association between angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and severe acute respiratory syndrome coronavirus 2 susceptibility, particularly via ACE-2 receptor upregulation in the kidneys, raises concerns about potential kidney disease risks in long coronavirus disease (COVID) patients. This study explores the association of ACEI/ARB therapy on acute kidney injury (AKI), chronic kidney disease (CKD) and all-cause mortality in patients with and without long COVID.</p></sec><sec id="abs2"><title>Methods</title><p>A retrospective cohort study using TriNetX datasets was conducted, with diagnoses of long COVID via <italic toggle="yes">International Classification of Diseases, Tenth Revision</italic> (ICD-10) codes and prescription for ACEI/ARB as the classification of four cohorts: long COVID ACEI/ARB users (LCAUs), long COVID ACEI/ARB non-users (LCANs), non-long COVID ACEI/ARB users (NLCAUs) and non-long COVID ACEI/ARB non-users (NLCANs). Multivariable stratified Cox proportional hazards regression models assessed the adjusted hazard ratios (aHRs) across groups. Additional analyses were conducted, including time-dependent exposure analysis and comparison with an active comparator, calcium channel blockers.</p></sec><sec id="abs3"><title>Results</title><p>Our study included 18&#8201;168 long COVID and 181&#8201;680 propensity score-matched non-long COVID patients from October 2021 to October 2023. ACEI/ARB use did not significantly affect the risk of AKI or CKD when comparing LCAUs with LCANs and NLCAUs with NLCANs. However, a protective effect against all-cause mortality was observed {aHR 0.79 [95% confidence interval (CI) 0.65&#8211;0.93]} in the NLCAU group compared with the NLCAN group. Conversely, long COVID was associated with increased risks of CKD [aHR 1.49 (95% CI 1.03&#8211;2.14)] and all-cause mortality [aHR 1.49 (95% CI 1.00&#8211;2.23)] when comparing LCANs with NLCANs. The additional analyses support the primary findings.</p></sec><sec id="abs4"><title>Conclusions</title><p>ACEI/ARB treatment does not increase the incidence of CKD or AKI, regardless of long COVID status. However, long COVID itself is associated with increasing risks of kidney diseases and all-cause mortality.</p></sec></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><p>
<fig position="float" id="ga1" orientation="portrait"><label>Graphical Abstract</label><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="sfae164fig1g.jpg"/></fig>
</p></abstract><kwd-group><kwd>acute kidney injury</kwd><kwd>angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs)</kwd><kwd>chronic kidney disease</kwd><kwd>long COVID</kwd><kwd>real-world analysis</kwd></kwd-group><counts><page-count count="11"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text position="float" orientation="portrait"><label>KEY LEARNING POINTS</label><p>
<bold>What was known:</bold>
</p><list list-type="bullet"><list-item><p>
<italic toggle="yes">In vitro</italic> studies suggest that the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) may increase the risk of severe acute respiratory syndrome coronavirus 2 entering cells, particularly in the kidney, thereby raising safety concerns regarding the use of ACEIs/ARBs.</p></list-item><list-item><p>Controversial conclusions have been drawn from current studies regarding whether the use of ACEIs/ARBs increases the risk of kidney diseases for patients without coronavirus disease 2019 (COVID-19).</p></list-item><list-item><p>Current studies indicate that ACEI/ARB use may be safe for COVID-19 patients in the short term, yet evidence remains insufficient from long-term follow-up, especially in cases of long COVID symptoms.</p></list-item></list><p>
<bold>This study adds:</bold>
</p><list list-type="bullet"><list-item><p>Utilizing real-world data from &gt;199&#160;848 patients in the USA, while using propensity score matching, this study confirms that the use of ACEIs/ARBs does not increase the risk of chronic kidney disease (CKD), acute kidney injury (AKI) or all-cause mortality.</p></list-item><list-item><p>This is the first study to demonstrate it is long COVID, not ACEI/ARB use, that increases the risk of CKD and higher mortality.</p></list-item><list-item><p>By comparing the use of ACEIs/ARBs and calcium channel blockers, our retrospective cohort study suggests that, contrary to findings from <italic toggle="yes">in vitro</italic> studies, the mechanism of ACEIs/ARBs may not increase the risk of kidney disease in a population study.</p></list-item></list><p>
<bold>Potential impact:</bold>
</p><list list-type="bullet"><list-item><p>This study provides evidence supporting the safe use of ACEIs/ARBs for both long COVID and non-long COVID patients over lengthy follow-up periods, guiding physician practice.</p></list-item><list-item><p>It emphasizes the necessity for increased focus on long COVID patients, particularly concerning their risk of progressing to CKD.</p></list-item><list-item><p>It illustrates the application of comprehensive methodologies through three independent study designs, offering a valuable template for addressing similar research questions in the future.</p></list-item></list></boxed-text><sec sec-type="intro" id="sec2"><title>INTRODUCTION</title><p>In the current post- coronavirus disease 2019 (COVID-19) pandemic period, the post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC), colloquially referred to as &#8216;long COVID&#8217;, has become a significant and ongoing public health challenge [<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>]. Kidney diseases have been reported as significant in PASC. Several retrospective cohort studies have observed increased risks of chronic kidney disease (CKD) and acute kidney injury (AKI) following COVID-19 infections [<xref rid="bib3" ref-type="bibr">3&#8211;6</xref>]. However, existing research predominantly addresses kidney complications following acute COVID-19 infections and overlooks the potential risk of kidney diseases in patients exhibiting long COVID symptoms. As of 1 October 2021, the introduction of a new <italic toggle="yes">International Classification of Diseases, Tenth Revision, Clinical Modification</italic> (ICD-10-CM) code, U09.9, in the USA for &#8216;Post COVID-19 condition, unspecified&#8217; [<xref rid="bib7" ref-type="bibr">7</xref>], facilitates more detailed research using real-world data to explore the risks of kidney diseases in patients presenting with post-COVID-19 conditions.</p><p>Meanwhile, as studies on the mechanism of SARS-CoV-2 continue, there is growing concern regarding the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) in patients with long COVID. SARS-CoV-2 primarily enters host cells by attaching its spike (S) protein to angiotensin-converting enzyme 2 (ACE2) [<xref rid="bib8" ref-type="bibr">8</xref>]. ACEI/ARB medications are known to upregulate ACE2 expression, notably in the kidneys [<xref rid="bib9" ref-type="bibr">9</xref>]. This information has led to widespread discussions about the safety of ACEI/ARB therapy for individuals with COVID-19. Also, given conflicting views on the relationship between ACEIs/ARBs and the occurrence of AKI [<xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>], determining whether ACEI/ARB use increases the risk of kidney diseases in long COVID patients is an urgent question.</p><p>In this study, our objective was to utilize national real-world clinical data to investigate whether patients with a long COVID diagnosis, who have a history of ACEI/ARB exposure, are at risk for adverse outcomes with continued use of these medications, considering the potential risk of kidney diseases. We executed three distinct study designs with the intention of thoroughly evaluating the impact of ACEI/ARB use on kidney diseases in individuals with and without long COVID.</p></sec><sec sec-type="materials|methods" id="sec3"><title>MATERIALS AND METHODS</title><sec id="sec3-1"><title>Data source</title><p>This analysis was conducted using a TriNetX database with data extracted from 1 October 2020 to 1 October 2023. TriNetX serves as a federated, multi-institutional health research network that compiles de-identified data derived from electronic health records (EHRs) across a broad spectrum of healthcare organizations [<xref rid="bib12" ref-type="bibr">12</xref>].</p></sec><sec id="sec3-2"><title>Cohort derivation and assessment of exposure</title><p>Long COVID patients, &gt;18&#160;years of age, were identified from 1 October 2021 to 1 October 2023 utilizing the ICD-10-CM code U09.9. The Centers for Disease Control and Prevention (CDC) officially characterizes long COVID as a post-COVID condition manifesting in patients with a confirmed or probable history of SARS-CoV-2 infection. The corresponding ICD-10 code for this condition became effective on 1 October 2021 [<xref rid="bib13" ref-type="bibr">13</xref>]. ACEI/ARB users were defined as patients who had any ACEI/ARB prescription history within 1&#160;year prior to the index dates, based on the medical prescription normalized code (RxNorm) [<xref rid="bib14" ref-type="bibr">14</xref>] and National Drug Code (NDC) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Appendix</xref>).</p><p>We identified 18&#160;793 patients coded as having long COVID, as well as 600&#160;000 control patients who were not diagnosed with COVID-19 infection or long COVID. Each group had at least 1&#160;month of follow-up after 1 October 2021. The index dates of the long COVID group were defined as the earliest diagnosis dates of long COVID. For the participants without long COVID, the earliest possible index date is 1 October 2021 and the latest index date is the maximum of the recorded dates for each patient, including diagnosis records, lab test results and medication records. Pseudo index dates were randomly assigned between these potential earliest and latest index dates for each patient [<xref rid="bib15" ref-type="bibr">15&#8211;18</xref>]. None of the patients in either group had a history of kidney disease prior to the index dates.</p><p>After all of the exclusion criteria were applied, we identified a total of 18&#160;168 eligible patients with long COVID and 447&#160;605 eligible patients without COVID infection or long COVID. Nearest-neighbour propensity score matching methods were further utilized at a 1:10 matching ratio using the &#8216;without replacement&#8217; sampling method [<xref rid="bib19" ref-type="bibr">19</xref>]. This approach led to the final selection of 18&#160;168 patients with long COVID and a corresponding control group of 181&#160;680 patients who were subjected to in-depth analysis (Fig.&#160;<xref rid="fig1" ref-type="fig">1</xref>). This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies [<xref rid="bib20" ref-type="bibr">20</xref>].</p><fig position="float" id="fig1" orientation="portrait"><label>Figure 1: </label><caption><p>Participant selection flow diagram for long COVID and non-long COVID groups from the TriNetX dataset.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="sfae164fig1.jpg"/></fig></sec><sec id="sec3-3"><title>Assessment of outcomes</title><p>The primary outcomes were the incidence of CKD (ICD-10 code N18) and AKI (ICD-10 code N17) identified after the index dates during the follow-up period. All-cause mortality, captured via the TriNetX platform from death registries or EHR histories, was also assessed.</p></sec><sec id="sec3-4"><title>Assessment of potential covariates</title><p>Demographic data on age (years), sex (male/female), race (White/Black or African American/unknown/other) and US regional location (South/West/Midwest/Northeast/unknown) were extracted directly from TriNetX patients&#8217; databases. Patients&#8217; comorbidities were assessed using the Elixhauser Comorbidity Index (ECI), within 1&#160;year prior to the index dates through ICD-10 codes [<xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>]. The nine most prevalent and potential kidney diseases or long COVID-related conditions, including congestive heart failure (CHF) [<xref rid="bib23" ref-type="bibr">23</xref>], hypertension [<xref rid="bib24" ref-type="bibr">24</xref>], diabetes [<xref rid="bib25" ref-type="bibr">25</xref>], obesity [<xref rid="bib26" ref-type="bibr">26</xref>], cardiac arrhythmia [<xref rid="bib27" ref-type="bibr">27</xref>], chronic pulmonary disease [<xref rid="bib28" ref-type="bibr">28</xref>], hypothyroidism [<xref rid="bib29" ref-type="bibr">29</xref>], solid tumour [<xref rid="bib30" ref-type="bibr">30</xref>] and depression [<xref rid="bib31" ref-type="bibr">31</xref>], were selected from the ECI results. Additionally, we evaluated the history of nine drugs&#8212;statins, diuretics, calcium channel blockers (CCBs), antiplatelets, anticoagulants, non-steroidal anti-inflammatory drugs, proton pump inhibitors, insulin and beta-blockers&#8212;used within the year preceding the index dates. These medications have been identified as potential risk factors for kidney disease [<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib32" ref-type="bibr">32</xref>].</p></sec><sec id="sec3-5"><title>Study design and statistical analysis</title><p>To achieve a thorough evaluation of the impact of ACEI/ARB use on kidney diseases in patients with or without long COVID, we utilized three independent study designs. This approach was intended to mitigate various biases and facilitate cross-validation among the different methods. A comprehensive study design diagram is presented in <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1</xref>, illustrating the rationale behind each aspect of the study.</p><sec id="sec3-5-1"><title>Primary analysis: four parallel cohorts design</title><p>We built four parallel cohorts with the status of long COVID and ACEI/ARB use histories, including long COVID ACEI/ARB users (LCAUs), long COVID non-users (LCANs), non-long COVID ACEI/ARB users (NLCAUs) and non-long COVID ACEI/ARB non-users (NLCANs), as shown in Fig.&#160;<xref rid="fig2" ref-type="fig">2</xref>. Propensity score matching with a 1:10 ratio was performed with individual covariates [age, gender, race, location, cardiovascular disease (CVD), hypertension and diabetes] and two-way interactions between covariates (race, CVD, hypertension and diabetes) in a binary logistic regression model to better control for baseline demographics and comorbidities [<xref rid="bib19" ref-type="bibr">19</xref>]. CVD was defined as the combination of one or more of CHF, cardiac arrhythmia, valvular disease, pulmonary circulation disorders and peripheral vascular disorders.</p><fig position="float" id="fig2" orientation="portrait"><label>Figure 2: </label><caption><p>Effects of ACEI/ARB use and long COVID on CKD, AKI and all-cause death. All models were adjusted for four demographic variables (age, gender, race and location), nine common comorbidities at baseline (CHF, hypertension, diabetes, obesity, cardiac arrhythmia, chronic pulmonary disease, hypothyroidism, solid tumour and depression) and histories of the use of nine drugs [statins, diuretics, antiplatelets, anticoagulants, CCBs, non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), insulin and beta-blockers].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="sfae164fig2.jpg"/></fig><p>We summarized baseline patients&#8217; characteristics across long COVID and non-long COVID groups, presented as before matching and after 1:10 matching. The standardized mean difference (SMD) was used as a measure to evaluate the matching result and an SMD &gt;0.1 was the threshold recommended for declaring imbalance [<xref rid="bib33" ref-type="bibr">33</xref>].</p><p>We calculated the person-time of follow-up for each participant following the index date to the first occurrence of an outcome of interest (CKD, AKI and all-cause death), death date (if applicable) or the maximum follow-up date (the latest date recorded in diagnosis records, lab test results and medication records), whichever occurred first. We conducted subgroup analyses by calculating the unadjusted incidence rates and corresponding 95% confidence intervals (CIs) per 1000 person-years of follow-up for the four cohorts within each subgroup. Subsequently, after confirming no violation of the proportional hazards assumption, we implemented stratified Cox proportional hazards regression models using a matching identifier constructed from the propensity scores for the outcomes of CKD, AKI and all-cause death separately. These models accounted for four demographic variables, nine common comorbidities and histories of the use of nine drugs, delivering an adjusted hazard ratio (aHR) with a 95% CI.</p><p>A sensitivity analysis was conducted to assess the impact of ACEI/ARB use and long COVID on kidney diseases, accounting for the competing risk of all-cause mortality, using the Fine&#8211;Gray subdistribution hazard model [<xref rid="bib34" ref-type="bibr">34</xref>]. The primary outcome measured was the time until the development of CKD or AKI as separate events. All-cause mortality was considered a competing event. Instances where neither CKD nor AKI developed, nor all-cause death occurred, were treated as censoring times.</p><p>A second sensitivity analysis was adjusted for additional covariates of estimated glomerular filtration rate (eGFR) and proteinuria. Specifically, eGFR was calculated based on creatinine values using the 2021 race-free Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation [<xref rid="bib35" ref-type="bibr">35</xref>]. If participants had multiple eGFR values within 1&#160;year prior to the index date, the mean eGFR was calculated. The Logical Observation Identifiers Names and Codes (LOINC) were employed to extract creatinine values [<xref rid="bib36" ref-type="bibr">36</xref>]. The history of proteinuria was identified using the ICD-10 code (R80). However, due to missing values in laboratory test results, this sensitivity analysis was conducted with a reduced sample size.</p></sec><sec id="sec3-5-2"><title>Additional analysis 1: time-dependent variable design</title><p>In the primary analysis, a potential concern was the random assignment of index dates and the possible immortal time bias introduced by the inconsistency between the ACEI/ARB use date and the diagnosed date of long COVID. To address these concerns, we incorporated time-dependent exposures for ACEI/ARB or long COVID separately to verify the results [<xref rid="bib37" ref-type="bibr">37</xref>, <xref rid="bib38" ref-type="bibr">38</xref>].</p><p>We extracted the earliest recorded date for each participant from a variety of sources within the dataset, including diagnosis records, laboratory test records and medication records. For those patients whose earliest recorded date fell on or before 1 October 2021, we established 1 October 2021 as their index date. Conversely, if the earliest recorded date occurred after 1 October 2021, we assigned this earliest date as the index date for these patients.</p><p>Stratified Cox proportional hazards regression models were implemented for the outcomes of CKD, AKI and all-cause death separately. To address potential biases, we introduced time-dependent variables into our model [<xref rid="bib39" ref-type="bibr">39</xref>]. Specifically, while investigating the effects of long COVID, time-dependent ACEI/ARB use was included as a covariate. Conversely, in analysing the impact of ACEI/ARB use, time-dependent long COVID status was incorporated as a covariate.</p></sec><sec id="sec3-5-3"><title>Additional analysis 2: active comparator cohort design</title><p>Another potential bias of this observational study design was the unmeasured confounding and selection bias. To mitigate these biases, we adopted a pharmaco-epidemiological approach known as the active comparator cohort design [<xref rid="bib40" ref-type="bibr">40</xref>]. Instead of comparing ACEI/ARB users with non-users as in previous analyses, this method involved contrasting ACEI/ARB use with CCB use. This approach aimed to examine any potential differences in kidney disease incidence between these groups. The principal strength of this research design was the likelihood of similar baselines between the groups, as both ACEIs/ARBs and CCBs are commonly prescribed drugs for the treatment of hypertension [<xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>]. Moreover, considering that ACEIs/ARBs could potentially facilitate the entry of SARS-CoV-2 into kidney cells [<xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>], this design allowed us to investigate whether the specific mechanism of ACEIs/ARBs could be correlated with an increased risk of kidney diseases in long COVID patients.</p><p>We constructed two cohorts: one with ACEI/ARB use and no CCB use and another with exclusive CCB use and no ACEI/ARB. Patients with histories of both ACEI/ARB and CCB use were excluded. The index dates corresponded to the initiation dates of these drugs. Multivariable Cox proportional hazards regression models were applied separately for the outcomes of CKD and AKI comparing the ACEI/ARB and CCB groups. These models adjusted for four demographic factors, nine prevalent comorbidities and the history of eight types of drug use (excluding CCB compared with the primary analysis), providing an aHR with a 95% CI. Due to the sample size limitation, all-cause death was not included in this analysis.</p><p>A third sensitivity analysis was conducted that included only patients &#8805;40&#160;years of age, based on the higher prevalence of hypertension in this age group [<xref rid="bib43" ref-type="bibr">43</xref>].</p><p>Data were analysed in R version 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria) and SAS version 9.4 (SAS Institute, Cary, NC, USA) using a two-tailed &#945; of 0.05.</p></sec></sec></sec><sec sec-type="results" id="sec4"><title>RESULTS</title><sec sec-type="results" id="sec4-1"><title>Primary analysis results</title><p>The present analysis incorporated 181&#160;680 non-long COVID patients {mean age 51.17&#160;years [standard deviation (SD) 14.7], 66.7% female, 73.5% White} and 18&#160;168 long COVID patients [mean age 50.61&#160;years (SD 14.6), 68.5% female, 72.9% White]. Prior to matching, imbalances in distribution were noted for patient regional location (SMD 0.235), baseline CVD status (SMD 0.428) and baseline hypertension status (SMD 0.255). After the matching process, we observed balanced distributions across all covariates, with all SMDs &lt;0.2 (Table&#160;<xref rid="tbl1" ref-type="table">1</xref>).</p><table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1:</label><caption><p>Distribution of matching variables and SMDs for participants with or without long COVID before and after matching.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th colspan="3" align="center" rowspan="1">Before matching</th><th colspan="3" align="center" rowspan="1">After 1:10 matching</th></tr><tr><th rowspan="1" colspan="1">Variables</th><th rowspan="1" colspan="1">No long COVID</th><th rowspan="1" colspan="1">Long COVID</th><th rowspan="1" colspan="1">SMD<xref rid="tb1fn1" ref-type="table-fn"><sup>a</sup></xref></th><th rowspan="1" colspan="1">No long COVID</th><th rowspan="1" colspan="1">Long COVID</th><th rowspan="1" colspan="1">SMD<xref rid="tb1fn1" ref-type="table-fn"><sup>a</sup></xref></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<italic toggle="yes">N</italic>
</td><td rowspan="1" colspan="1">447&#160;605</td><td rowspan="1" colspan="1">18&#160;168</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">181&#160;680</td><td rowspan="1" colspan="1">18&#160;168</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Age (years), mean (SD)</td><td rowspan="1" colspan="1"> 51.16 (18.0)</td><td rowspan="1" colspan="1">50.61 (14.6)</td><td rowspan="1" colspan="1">0.033</td><td rowspan="1" colspan="1"> 51.17 (14.7)</td><td rowspan="1" colspan="1">50.61 (14.6)</td><td rowspan="1" colspan="1">0.033</td></tr><tr><td rowspan="1" colspan="1">Female, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">271&#160;079 (60.6)</td><td rowspan="1" colspan="1">12&#160;439 (68.5)</td><td rowspan="1" colspan="1">0.166</td><td rowspan="1" colspan="1">121&#160;227 (66.7)</td><td rowspan="1" colspan="1">12&#160;439 (68.5)</td><td rowspan="1" colspan="1">0.037</td></tr><tr><td rowspan="1" colspan="1">Race, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.131</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.020</td></tr><tr><td rowspan="1" colspan="1">&#8195;White</td><td rowspan="1" colspan="1">303&#160;843 (67.9)</td><td rowspan="1" colspan="1">13&#160;236 (72.9)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">133&#160;605 (73.5)</td><td rowspan="1" colspan="1">13&#160;236 (72.9)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Black or African American</td><td rowspan="1" colspan="1">61&#160;237 (13.7)</td><td rowspan="1" colspan="1">1801 (9.9)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">17&#160;044 (9.4)</td><td rowspan="1" colspan="1">1801 (9.9)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Unknown</td><td rowspan="1" colspan="1">62&#160;253 (13.9)</td><td rowspan="1" colspan="1">2445 (13.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">24&#160;109 (13.3)</td><td rowspan="1" colspan="1">2445 (13.5)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Other</td><td rowspan="1" colspan="1">20&#160;272 (4.5)</td><td rowspan="1" colspan="1">686 (3.8)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">6922 (3.8)</td><td rowspan="1" colspan="1">686 (3.8)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Location, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.235</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.027</td></tr><tr><td rowspan="1" colspan="1">&#8195;Midwest</td><td rowspan="1" colspan="1">73&#160;680 (16.5)</td><td rowspan="1" colspan="1">3593 (19.8)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">36&#160;416 (20.0)</td><td rowspan="1" colspan="1">3593 (19.8)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Northeast</td><td rowspan="1" colspan="1">127&#160;131 (28.4)</td><td rowspan="1" colspan="1">4958 (27.3)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">51&#160;405 (28.3)</td><td rowspan="1" colspan="1">4958 (27.3)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;South</td><td rowspan="1" colspan="1">188&#160;957 (42.2)</td><td rowspan="1" colspan="1">6063 (33.4)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">59&#160;077 (32.5)</td><td rowspan="1" colspan="1">6063 (33.4)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;West</td><td rowspan="1" colspan="1">57&#160;837 (12.9)</td><td rowspan="1" colspan="1">3554 (19.6)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">34&#160;782 (19.1)</td><td rowspan="1" colspan="1">3554 (19.6)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">CVD, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">36&#160;920 (8.2)</td><td rowspan="1" colspan="1">4280 (23.6)</td><td rowspan="1" colspan="1">0.428</td><td rowspan="1" colspan="1">30&#160;801 (17.0)</td><td rowspan="1" colspan="1">4280 (23.6)</td><td rowspan="1" colspan="1">0.165</td></tr><tr><td rowspan="1" colspan="1">Hypertension, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">74&#160;156 (16.6)</td><td rowspan="1" colspan="1">4908 (27.0)</td><td rowspan="1" colspan="1">0.255</td><td rowspan="1" colspan="1">48&#160;118 (26.5)</td><td rowspan="1" colspan="1">4908 (27.0)</td><td rowspan="1" colspan="1">0.012</td></tr><tr><td rowspan="1" colspan="1">Diabetes, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">29&#160;970 (6.7)</td><td rowspan="1" colspan="1">2075 (11.4)</td><td rowspan="1" colspan="1">0.165</td><td rowspan="1" colspan="1">18&#160;706 (10.3)</td><td rowspan="1" colspan="1">2075 (11.4)</td><td rowspan="1" colspan="1">0.036</td></tr></tbody></table><table-wrap-foot><fn id="tb1fn1"><p>
<sup>a</sup>An SMD &gt;0.2 is a threshold recommended for declaring imbalance.</p></fn></table-wrap-foot></table-wrap><p>After the matching process, it was evident that the group using ACEIs/ARBs included older individuals and a smaller proportion of females compared with the group not taking ACEIs/ARBs. Furthermore, the ACEI/ARB users exhibited a higher prevalence of all nine comorbidities at baseline. These trends were consistent across both long COVID and non-long COVID patients. Additionally, the LCAU group presented the highest prevalence of CHF (10.5%), hypertension (79.1%), diabetes (32.2%), obesity (35.6%), cardiac arrhythmia (23.6%), chronic pulmonary disease (29.1%), hypothyroidism (14.2%) and depression (25.4%) when compared with the other three parallel cohorts (Table&#160;<xref rid="tbl2" ref-type="table">2</xref>). These statistics highlight the comparatively poorer baseline health conditions of the LCAU group.</p><table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2:</label><caption><p>Demographic and clinical characteristics stratified by ACEI/ARB use and long COVID status after 1:10 matching.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th colspan="2" align="center" rowspan="1">No long COVID (<italic toggle="yes">n</italic>&#160;=&#160;181&#160;680)</th><th colspan="2" align="center" rowspan="1">Long COVID (n&#160;=&#160;18&#160;168)</th></tr><tr><th rowspan="1" colspan="1">Characteristics</th><th rowspan="1" colspan="1">No ACEI/ARB (<break/><italic toggle="yes">n</italic>&#160;=&#160;156&#160;129)</th><th rowspan="1" colspan="1">ACEI/ARB (<break/><italic toggle="yes">n</italic>&#160;=&#160;25&#160;551)</th><th rowspan="1" colspan="1">No ACEI/ARB (<break/><italic toggle="yes">n</italic>&#160;=&#160;15&#160;307)</th><th rowspan="1" colspan="1">ACEI/ARB<break/> (<italic toggle="yes">n</italic>&#160;=&#160;2861)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years), mean (SD)</td><td rowspan="1" colspan="1">50.6 (14.7)</td><td rowspan="1" colspan="1">60.2 (11.9)</td><td rowspan="1" colspan="1">50.0 (14.6)</td><td rowspan="1" colspan="1">59.2 (11.9)</td></tr><tr><td rowspan="1" colspan="1">Female, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">107&#160;510 (68.9)</td><td rowspan="1" colspan="1">13&#160;717 (53.7)</td><td rowspan="1" colspan="1">10&#160;773 (70.4)</td><td rowspan="1" colspan="1">1666 (58.2)</td></tr><tr><td rowspan="1" colspan="1">Race, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;White</td><td rowspan="1" colspan="1">114&#160;465 (73.3)</td><td rowspan="1" colspan="1">19&#160;140 (74.9)</td><td rowspan="1" colspan="1">11&#160;165 (72.9)</td><td rowspan="1" colspan="1">2071 (72.4)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Black or African American</td><td rowspan="1" colspan="1">14&#160;086 (9.0)</td><td rowspan="1" colspan="1">2958 (11.6)</td><td rowspan="1" colspan="1">1432 (9.4)</td><td rowspan="1" colspan="1">369 (12.9)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Unknown</td><td rowspan="1" colspan="1">21&#160;331 (13.7)</td><td rowspan="1" colspan="1">2778 (10.9)</td><td rowspan="1" colspan="1">2109 (13.8)</td><td rowspan="1" colspan="1">336 (11.7)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Other</td><td rowspan="1" colspan="1">6247 (4.0)</td><td rowspan="1" colspan="1">675 (2.6)</td><td rowspan="1" colspan="1">601 (3.9)</td><td rowspan="1" colspan="1">85 (3.0)</td></tr><tr><td rowspan="1" colspan="1">Location, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Midwest</td><td rowspan="1" colspan="1">30&#160;710 (19.7)</td><td rowspan="1" colspan="1">5706 (22.3)</td><td rowspan="1" colspan="1">2942 (19.2)</td><td rowspan="1" colspan="1">651 (22.8)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Northeast</td><td rowspan="1" colspan="1">44&#160;244 (28.3)</td><td rowspan="1" colspan="1">7161 (28.0)</td><td rowspan="1" colspan="1">4314 (28.2)</td><td rowspan="1" colspan="1">644 (22.5)</td></tr><tr><td rowspan="1" colspan="1">&#8195;South</td><td rowspan="1" colspan="1">50&#160;193 (32.1)</td><td rowspan="1" colspan="1">8884 (34.8)</td><td rowspan="1" colspan="1">4947 (32.3)</td><td rowspan="1" colspan="1">1116 (39.0)</td></tr><tr><td rowspan="1" colspan="1">&#8195;West</td><td rowspan="1" colspan="1">30&#160;982 (19.8)</td><td rowspan="1" colspan="1">3800 (14.9)</td><td rowspan="1" colspan="1">3104 (20.3)</td><td rowspan="1" colspan="1">450 (15.7)</td></tr><tr><td rowspan="1" colspan="1">CHF, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">2902 (1.8)</td><td rowspan="1" colspan="1">2817 (11.0)</td><td rowspan="1" colspan="1">357 (2.3)</td><td rowspan="1" colspan="1">300 (10.5)</td></tr><tr><td rowspan="1" colspan="1">Hypertension, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">26&#160;657 (17.1)</td><td rowspan="1" colspan="1">21&#160;461 (84.0)</td><td rowspan="1" colspan="1">2644 (17.3)</td><td rowspan="1" colspan="1">2264 (79.1)</td></tr><tr><td rowspan="1" colspan="1">Diabetes, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">11&#160;076 (7.1)</td><td rowspan="1" colspan="1">7630 (29.9)</td><td rowspan="1" colspan="1">1155 (7.5)</td><td rowspan="1" colspan="1">920 (32.2)</td></tr><tr><td rowspan="1" colspan="1">Obesity, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">11&#160;707 (7.5)</td><td rowspan="1" colspan="1">5838 (22.8)</td><td rowspan="1" colspan="1">2404 (15.7)</td><td rowspan="1" colspan="1">1018 (35.6)</td></tr><tr><td rowspan="1" colspan="1">Cardiac arrhythmia, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">14&#160;302 (9.2)</td><td rowspan="1" colspan="1">4983 (19.5)</td><td rowspan="1" colspan="1">2416 (15.8)</td><td rowspan="1" colspan="1">674 (23.6)</td></tr><tr><td rowspan="1" colspan="1">Chronic pulmonary disease, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">9669 (6.2)</td><td rowspan="1" colspan="1">3426 (13.4)</td><td rowspan="1" colspan="1">3027 (19.8)</td><td rowspan="1" colspan="1">833 (29.1)</td></tr><tr><td rowspan="1" colspan="1">Hypothyroidism, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">9384 (6.0)</td><td rowspan="1" colspan="1">2917 (11.4)</td><td rowspan="1" colspan="1">1356 (8.9)</td><td rowspan="1" colspan="1">405 (14.2)</td></tr><tr><td rowspan="1" colspan="1">Solid tumour, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">6479 (4.2)</td><td rowspan="1" colspan="1">1768 (6.9)</td><td rowspan="1" colspan="1">392 (2.6)</td><td rowspan="1" colspan="1">182 (6.4)</td></tr><tr><td rowspan="1" colspan="1">Depression, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">11&#160;774 (7.5)</td><td rowspan="1" colspan="1">3495 (13.7)</td><td rowspan="1" colspan="1">2815 (18.4)</td><td rowspan="1" colspan="1">726 (25.4)</td></tr></tbody></table></table-wrap><p>In evaluating crude incidence rates per 1000 person-years, LCAUs presented incidence rates for CKD (33.2 cases/1000 person-years) and AKI (34.1 cases/1000 person-years), which were higher than the incidence rate for LCANs with CKD (14.3 cases/1000 person-years) and AKI (14.5 cases/1000 person-years) when accounting for long COVID status while comparing the impact of ACEI/ARB use. Similarly, with ACEI/ARB use and assessing long COVID's influence, LCAUs maintained a higher incidence rate than NLCAUs, evidenced by 29.3 cases of CKD and 25.9 cases of AKI per 1000 person-years (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>).</p><p>Stratified Cox proportional hazards models were used to assess the influence of ACEI/ARB use within the long COVID and non-long COVID cohorts, as well as the impact of long COVID among individuals with and without ACEI/ARB use. ACEI/ARB use did not significantly influence the incidence of CKD or AKI in either the long COVID [CKD: aHR 1.03 (95% CI 0.76&#8211;1.40), AKI: aHR 0.96 (95% CI 0.71&#8211;1.30)] or non-long COVID cohorts [CKD: aHR 1.15 (95% CI 0.97&#8211;1.36), AKI: aHR 1.05 (95% CI 0.88&#8211;1.26)]. Furthermore, although ACEI/ARB use did not markedly affect all-cause mortality in the long COVID cohort [aHR 0.67 (95% CI 0.42&#8211;1.05)], it did exhibit a significant protective effect against all-cause mortality in the non-long COVID cohort [aHR 0.79 (95% CI 0.65&#8211;0.93)]. Moreover, in patients without ACEI/ARB use, long COVID had a significant effect on the incidence of CKD [aHR 1.49 (95% CI 1.03&#8211;2.14)] and all-cause mortality [aHR 1.49 (95% CI 1.00&#8211;2.23)]. However, the effect on AKI was not significant [aHR 1.26 (95% CI 0.85&#8211;1.89)]. In contrast, among individuals taking ACEIs/ARBs, these associations were not statistically significant, with aHRs of 1.02 (95% CI 0.66&#8211;1.61) for CKD, 1.36 (95% CI 0.81&#8211;2.26) for AKI and 0.56 (95% CI 0.19&#8211;1.31) for all-cause mortality (Fig.&#160;<xref rid="fig2" ref-type="fig">2</xref>).</p><p>The first sensitivity analysis, accounting for the competing risk of all-cause mortality, yielded consistent results for CKD across four scenarios. However, when examining the aHR for the impact of long COVID in both the ACEI/ARB use and non-use groups, long COVID demonstrated a significantly increasing effect on the incidence of AKI. This result was observed after adjusting for the competing risk of all-cause mortality and the same covariates in the primary analysis (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>).</p><p>The second sensitivity analysis included 12&#160;732 patients with long COVID and 59&#160;779 control patients. The results of this sensitivity analysis were consistent with those of the primary analysis (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S3</xref>).</p></sec><sec sec-type="results" id="sec4-2"><title>Additional analysis 1 results</title><p>When treating the status of long COVID as a time-dependent variable to assess the effects of ACEI/ARB use in the entire population, we found that ACEI/ARB use did not exhibit significant effects on either CKD [aHR 1.11 (95% CI 0.95&#8211;1.29)] or AKI [aHR 0.97 (95% CI 0.83&#8211;1.14)]. However, ACEI/ARB use demonstrated a significant protective effect against all-cause mortality [aHR 0.77 (95% CI 0.65, 0.91)]. Furthermore, when considering ACEI/ARB use as a time-dependent variable, long COVID had a significant impact on CKD [aHR 1.47 (95% CI 1.03&#8211;2.10)] and AKI [aHR 1.55 (95% CI 1.04&#8211;2.31)] but no significant effect on AKI [aHR 1.32 (95% CI 0.89&#8211;1.96)], as shown in Fig.&#160;<xref rid="fig3" ref-type="fig">3</xref>.</p><fig position="float" id="fig3" orientation="portrait"><label>Figure 3: </label><caption><p>Effects of ACEI/ARB use and long COVID on CKD, AKI and all-cause death with time-dependent long COVID and ACEI/ARB status. All models were adjusted for four demographic variables (age, gender, race and location), nine common comorbidities at baseline (CHF, hypertension, diabetes, obesity, cardiac arrhythmia, chronic pulmonary disease, hypothyroidism, solid tumour and depression) and histories of the use of nine drugs [statins, diuretics, antiplatelets, anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs), CCBs, proton pump inhibitors (PPIs), insulin and beta-blockers].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="sfae164fig3.jpg"/></fig></sec><sec sec-type="results" id="sec4-3"><title>Additional analysis 2 results</title><p>Overall, ACEI/ARB users and CCB users exhibited similar demographic distributions and baseline comorbidities. Nevertheless, the ACEI/ARB group had a lower proportion of females compared with the CCB group, a higher proportion of White individuals and a lower proportion of Black individuals and an increased prevalence of diabetes (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S4</xref>).</p><p>We observed no significantly elevated hazards in patients on ACEIs/ARBs compared with those on CCBs in the long COVID group. The aHR for ACEI/ARB use relative to CCBs on CKD was 0.89 (95% CI 0.57&#8211;1.38) and on AKI was 1.06 (95% CI 0.63&#8211;1.79), after accounting for demographics, baseline comorbidities and other drug use histories. Comparable non-significant results were also noted in non-long COVID groups (Fig.&#160;<xref rid="fig4" ref-type="fig">4</xref>).</p><fig position="float" id="fig4" orientation="portrait"><label>Figure 4: </label><caption><p>Comparison of ACEI/ARB use with the active comparator, CCBs, with aHRs (95% CIs) for CKD and AKI in both long COVID and non-long COVID subgroups. All models were adjusted for four demographic variables (age, gender, race and location), nine common comorbidities at baseline (CHF, hypertension, diabetes, obesity, cardiac arrhythmia, chronic pulmonary disease, hypothyroidism, solid tumour and depression) and histories of the use of eight drugs [statins, diuretics, antiplatelets, anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), insulin and beta-blockers].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="sfae164fig4.jpg"/></fig><p>The sensitivity analysis conducted on the subgroup &#8805;40&#160;years of age demonstrated results consistent with those observed in additional analysis 2 (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S5</xref>).</p></sec></sec><sec sec-type="discussion" id="sec5"><title>DISCUSSION</title><p>From our study, our primary conclusion is that the use of ACEIs/ARBs does not appear to elevate the risk of CKD or AKI with long COVID patients. Second, our findings suggest that long COVID may increase the risk of CKD and potentially increase the risk of all-cause mortality. Lastly, ACEI/ARB use appears to offer a protective effect against all-cause mortality in patients without long COVID.</p><p>To the best of our knowledge, this study is the first to clearly explain the complex effects of long COVID and the use of ACEIs/ARBs on kidney diseases. Additionally, our research serves as an extension, providing insights into the long-term effects of COVID-19 on kidney diseases, especially accounting for the competing risk of death and time-dependent effects of ACEI/ARB use or a long COVID diagnosis. Moreover, this comparison between ACEIs/ARBs and CCBs is the first to examine the ACEI/ARB mechanism leveraging real-world data with long COVID patients.</p><sec id="sec5-1"><title>Consistency of ACEI/ARB effects with previous studies</title><p>Our findings confirm the results of prior studies. First, our findings align with earlier research on the use of ACEIs/ARBs for kidney diseases and all-cause death. A prospective cohort study investigating the link between ACEI/ARB use and recurrent AKI post-hospitalization found that the use of ACEIs/ARBs did not heighten the risk of recurrent AKI [<xref rid="bib10" ref-type="bibr">10</xref>]. Additionally, several retrospective cohort studies examining ACEI/ARB use following AKI also highlighted their protective effects against all-cause death [<xref rid="bib44" ref-type="bibr">44</xref>, <xref rid="bib45" ref-type="bibr">45</xref>].</p><p>In the context of COVID-19 and its acute outcomes, our findings agree with the results of several key studies. A randomized clinical trial involving 659 patients (334 in the discontinuation group and 325 in the continuation group) who were hospitalized with mild&#8211;moderate COVID-19 and were on ACEIs/ARBs prior to admission showed no significant difference in the mean number of days alive and out of the hospital between the discontinuation and continuation groups [<xref rid="bib46" ref-type="bibr">46</xref>]. Additionally, a multicentre prospective cohort study of 1129 hospitalized COVID-19 patients with hypertension revealed that inpatient use of ACEIs/ARBs was linked to a lower risk of all-cause mortality compared with non-users [<xref rid="bib47" ref-type="bibr">47</xref>]. Although these studies are characterized by relatively short follow-up periods and primarily focus on acute outcomes after COVID-19, their results are consistent with our findings over longer periods, particularly in relation to the effects of long COVID.</p><p>Lastly, guidelines from the European [<xref rid="bib48" ref-type="bibr">48</xref>] and American [<xref rid="bib49" ref-type="bibr">49</xref>] Societies of Cardiology advised against routinely discontinuing ACEIs/ARBs in response to the COVID-19 pandemic. Our findings further extend this guidance by suggesting that for individuals with long COVID, the routine cessation of ACEI/ARB treatment is not indicated.</p></sec><sec id="sec5-2"><title>Long COVID effects on kidney diseases</title><p>Our study primarily revealed that long COVID is associated with an increased risk of CKD and all-cause mortality, but not AKI. Previous cohort studies with 1&#160;726&#160;683 US veterans showed increased risks of AKI, end-stage kidney disease and major adverse kidney events shortly after COVID-19 infections among 30-day survivors, with a median follow-up of &#8776;172&#160;days [<xref rid="bib6" ref-type="bibr">6</xref>]. In our study design, we specifically excluded individuals who had a prior diagnosis of AKI or CKD before the index dates, focusing solely on the incidence of new AKI or CKD cases after diagnosis of long COVID. This methodological approach likely explains why our study observed an increased risk of CKD but did not find a significant association with AKI, as we excluded those who developed AKI immediately following COVID-19 infection and only focused on effects of a long COVID diagnosis.</p></sec><sec id="sec5-3"><title>Competing risk effect of all-cause mortality</title><p>To assess the competing effect of all-cause mortality on CKD and AKI, we performed sensitivity analyses for both the exposure to ACEIs/ARBs and long COVID, as outlined in our primary analysis. After adjusting for the competing risk of all-cause death, the association of ACEI/ARB use with both CKD and AKI remained non-significant. This outcome supports the validity of our results with ACEI/ARB use.</p><p>In our primary analysis, we found that long COVID increased the risk of all-cause mortality. Subsequently, we performed a sensitivity analysis, adjusting for the competing risk of all-cause death, that revealed a significantly increased risk of AKI. This finding can be seen in the strong correlation between hospitalization for AKI and mortality [<xref rid="bib50" ref-type="bibr">50</xref>, <xref rid="bib51" ref-type="bibr">51</xref>]. It is plausible that all-cause mortality might preclude the development of AKI in some patients. Therefore, when evaluating the impact of long COVID-19, considering the competing risk of all-cause death is crucial, as it may transform an effect from non-significant to significant.</p></sec><sec id="sec5-4"><title>Comparison between ACEI/ARB use and CCB use</title><p>We selected CCBs as an active comparator to ACEIs/ARBs due to their common use in treating hypertension, albeit through differing mechanisms [<xref rid="bib52" ref-type="bibr">52</xref>]. Our underlying assumption was that ACEI/ARB users and CCB users would have comparable comorbidities and health conditions, potentially sharing similar unmeasured confounders. Thus, any observed difference in outcomes likely stems from the mechanistic differences between ACEIs/ARBs and CCBs.</p><p>In additional analysis 2, we conducted a sensitivity analysis focusing exclusively on patients &#8805;40&#160;years of age, a demographic with a higher prevalence of hypertension [<xref rid="bib43" ref-type="bibr">43</xref>]. The consistency of these results with those of additional analysis 2 further validate our findings.</p></sec><sec id="sec5-5"><title>Strengths and limitations of the study</title><p>A strength of this analysis is the use of multiple study designs to increase the rigor of the work. We employed three distinct study designs, mitigating potential biases and yielding consistent conclusions across each one. The four parallel cohorts design (primary analysis) was straightforward, allowing us to compare the effects of ACEI/ARB use and long COVID under different comparisons. Our matching strategy facilitated the creation of cohorts with similar baseline characteristics and reduced the selection bias [<xref rid="bib53" ref-type="bibr">53</xref>]. The time-dependent variable design (additional analysis 1) addressed the bias introduced by a randomly assigned index for the non-long COVID group in the primary analysis, and it effectively minimized the immortal time bias [<xref rid="bib37" ref-type="bibr">37</xref>, <xref rid="bib38" ref-type="bibr">38</xref>]. The active comparator design (additional analysis 2) was implemented to compare ACEI/ARB and CCB use head to head [<xref rid="bib40" ref-type="bibr">40</xref>]. All three study designs demonstrated the non-significant association between ACEI/ARB use and kidney diseases, regardless of long COVID status. Both the primary analysis and additional analysis 1 included all-cause mortality, revealing the potential protective effects of ACEIs/ARBs. Primary analysis and additional analysis 1 also assessed the effects of long COVID, with both suggesting that long COVID could increase the risk of CKD.</p><p>The interaction term test reinforces the validity of our study results, demonstrating that the observed outcomes can be attributed directly to either ACEI/ARB use or long COVID. Prior to our main analysis, we incorporated an interaction term for long COVID status and ACEI/ARB use into the Cox proportional hazards regression model for CKD and AKI across the total population. We found that the effects of this interaction term were not statistically significant (CKD, <italic toggle="yes">P</italic>&#160;=&#160;.681; AKI, <italic toggle="yes">P</italic>&#160;=&#160;.438), indicating that the observed outcomes related to long COVID (or ACEI/ARB use) in our study are attributable to long COVID (or ACEI/ARB use) itself rather than being modified by ACEI/ARB use (or long COVID).</p><p>The extensive real-world dataset we used adds considerable strength to our study. With the recent assignment of the ICD-10 code for long COVID, to the best of our knowledge, ours is the first study examining the effects of long COVID on kidney diseases within a substantial real-world sample, including 199&#160;848 patients. Also, our research incorporates the latest data available through 1 October 2023, with a 2-year period of follow-up for long COVID patients from 1 October 2021.</p><p>Our study also has some limitations. First, due to the nature of observational studies, causality cannot be definitively established. Second, we acknowledge the potential pitfalls of EHR databases compared with prospective clinical trials: patients might be misclassified due to misreporting or underreporting of diagnostic codes or medications. Third, despite our efforts to exclude patients with long COVID or COVID-19 diagnoses or those testing positive for SARS-CoV-2, it is possible that some individuals in the control group had undiagnosed mild or asymptomatic COVID-19 because they were not tested for infection. Such non-differential misclassification of exposure could potentially underestimate the strength of the association between long COVID and the onset of CKD, AKI or all-cause death.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data" orientation="portrait"><label>sfae164_Supplemental_File</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sfae164_supplemental_file.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ack1"><title>ACKNOWLEDGEMENTS</title><p>The protocol for this study was reviewed and received a determination of non-human subjects&#8217; research by the Penn State Institutional Review Board. The individual informed consent requirement was waived for this secondary analysis of de-identified data.</p></ack><sec id="sec7"><title>FUNDING</title><p>There was no external or internal funding supporting this study.</p></sec><sec id="sec8"><title>AUTHORS&#8217; CONTRIBUTIONS</title><p>Y.Z., D.M.B. and V.M.C. designed the research (project conception, development of overall research plan). Y.Z. and D.M.B. were responsible for data extraction, data analysis and study oversight. Y.Z. performed the statistical analysis and wrote the first draft of the manuscript. All authors reviewed and edited the manuscript and read and approved the final manuscript. This study is part of the YZ&#8217;s doctoral dissertation research project with the Penn State College of Medicine, United States of America.</p></sec><sec sec-type="data-availability" id="sec9"><title>DATA AVAILABILITY STATEMENT</title><p>Data are available from TriNetX.</p></sec><sec sec-type="COI-statement" id="sec10"><title>CONFLICT OF INTEREST STATEMENT</title><p>None declared.</p></sec><ref-list id="ref1"><title>REFERENCES</title><ref id="bib1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ford</surname> &#160;<given-names>ND</given-names></string-name></person-group>. <article-title>Long COVID and significant activity limitation among adults, by age&#8212;United States, June 1&#8211;13, 2022, to June 7&#8211;19, 2023</article-title>. <source>MMWR Morb Mortal Wkly Rep</source> &#160;<year>2023</year>;<volume>72</volume>:<fpage>866</fpage>&#8211;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.15585/mmwr.mm7232a3</pub-id><pub-id pub-id-type="pmid">37561665</pub-id><pub-id pub-id-type="pmcid">PMC10415000</pub-id></mixed-citation></ref><ref id="bib2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Groff</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ssentongo</surname> &#160;<given-names>AE</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review</article-title>. <source>JAMA Netw Open</source> &#160;<year>2021</year>;<volume>4</volume>:<fpage>e2128568</fpage>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.28568</pub-id><pub-id pub-id-type="pmid">34643720</pub-id><pub-id pub-id-type="pmcid">PMC8515212</pub-id></mixed-citation></ref><ref id="bib3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fisher</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Neugarten</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bellin</surname> &#160;<given-names>E</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>AKI in hospitalized patients with and without COVID-19: a comparison study</article-title>. <source>J Am Soc Nephrol</source> &#160;<year>2020</year>;<volume>31</volume>:<fpage>2145</fpage>&#8211;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2020040509</pub-id><pub-id pub-id-type="pmid">32669322</pub-id><pub-id pub-id-type="pmcid">PMC7461660</pub-id></mixed-citation></ref><ref id="bib4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Winkelmayer</surname> &#160;<given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Khairallah</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Charytan</surname> &#160;<given-names>DM</given-names></string-name></person-group>. <article-title>Nephrology and COVID-19</article-title>. <source>JAMA</source> &#160;<year>2020</year>;<volume>324</volume>:<fpage>1137</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.16779</pub-id><pub-id pub-id-type="pmid">32960255</pub-id></mixed-citation></ref><ref id="bib5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nugent</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Aklilu</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yamamoto</surname> &#160;<given-names>Y</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Assessment of acute kidney injury and longitudinal kidney function after hospital discharge among patients with and without COVID-19</article-title>. <source>JAMA Netw Open</source> &#160;<year>2021</year>;<volume>4</volume>:<fpage>e211095</fpage>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.1095</pub-id><pub-id pub-id-type="pmid">33688965</pub-id><pub-id pub-id-type="pmcid">PMC7948062</pub-id></mixed-citation></ref><ref id="bib6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bowe</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname> &#160;<given-names>E</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Kidney outcomes in long COVID</article-title>. <source>J Am Soc Nephrol</source> &#160;<year>2021</year>;<volume>32</volume>:<fpage>2851</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2021060734</pub-id><pub-id pub-id-type="pmid">34470828</pub-id><pub-id pub-id-type="pmcid">PMC8806085</pub-id></mixed-citation></ref><ref id="bib7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pfaff</surname> &#160;<given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Madlock-Brown</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Baratta</surname> &#160;<given-names>JM</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Coding long COVID: characterizing a new disease through an ICD-10 lens</article-title>. <source>BMC Med</source> &#160;<year>2023</year>;<volume>21</volume>:<fpage>58</fpage>. <pub-id pub-id-type="doi">10.1101/2022.04.18.22273968</pub-id><pub-id pub-id-type="pmid">36793086</pub-id><pub-id pub-id-type="pmcid">PMC9931566</pub-id></mixed-citation></ref><ref id="bib8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jackson</surname> &#160;<given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Farzan</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname> &#160;<given-names>B</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Mechanisms of SARS-CoV-2 entry into cells</article-title>. <source>Nat Rev Mol Cell Biol</source> &#160;<year>2022</year>;<volume>23</volume>:<fpage>3</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-021-00418-x</pub-id><pub-id pub-id-type="pmid">34611326</pub-id><pub-id pub-id-type="pmcid">PMC8491763</pub-id></mixed-citation></ref><ref id="bib9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khan</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname> &#160;<given-names>CR</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Does SARS-CoV-2 infect the kidney?</article-title> &#160;<source>J Am Soc Nephrol</source> &#160;<year>2020</year>;<volume>31</volume>:<fpage>2746</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2020081229</pub-id><pub-id pub-id-type="pmid">33051359</pub-id><pub-id pub-id-type="pmcid">PMC7790203</pub-id></mixed-citation></ref><ref id="bib10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brar</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname> &#160;<given-names>KD</given-names></string-name>, <string-name name-style="western"><surname>Go</surname> &#160;<given-names>AS</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Prospective cohort study of renin-angiotensin system blocker usage after hospitalized acute kidney injury</article-title>. <source>Clin J Am Soc Nephrol</source> &#160;<year>2021</year>;<volume>16</volume>:<fpage>26</fpage>&#8211;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.2215/CJN.10840720</pub-id><pub-id pub-id-type="pmcid">PMC7792656</pub-id><pub-id pub-id-type="pmid">33272913</pub-id></mixed-citation></ref><ref id="bib11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bidulka</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname> &#160;<given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Leyrat</surname> &#160;<given-names>C</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care</article-title>. <source>BMC Med</source> &#160;<year>2020</year>;<volume>18</volume>:<fpage>195</fpage>. <pub-id pub-id-type="doi">10.1186/s12916-020-01659-x</pub-id><pub-id pub-id-type="pmid">32723383</pub-id><pub-id pub-id-type="pmcid">PMC7389346</pub-id></mixed-citation></ref><ref id="bib12"><label>12.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>TriNetX</collab></person-group>. <article-title>Publication guidelines</article-title>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://trinetx.com/real-world-resources/publications/trinetx-publication-guidelines/" ext-link-type="uri">https://trinetx.com/real-world-resources/publications/trinetx-publication-guidelines/</ext-link> [accessed 1 July 2023]</comment>.</mixed-citation></ref><ref id="bib13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention</collab></person-group>. <article-title>Clinical overview of long COVID</article-title>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html" ext-link-type="uri">https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html</ext-link> [accessed 2 July 2023]</comment>.</mixed-citation></ref><ref id="bib14"><label>14.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>National Library of Medicine</collab></person-group>. <article-title>RxNorm overview</article-title>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nlm.nih.gov/research/umls/rxnorm/overview.html" ext-link-type="uri">https://www.nlm.nih.gov/research/umls/rxnorm/overview.html</ext-link> [accessed 28 October 2023]</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15360280801989377</pub-id><pub-id pub-id-type="pmid">28792816</pub-id></mixed-citation></ref><ref id="bib15"><label>15.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>Harvey</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Jankus</surname> &#160;<given-names>DD</given-names></string-name>, <string-name name-style="western"><surname>Mosley</surname> &#160;<given-names>D</given-names></string-name></person-group>. <article-title>Random assignment of proxy event dates to unexposed individuals in observational studies: an automated technique using SAS<sup>&#174;</sup></article-title>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://mwsug.org/proceedings/2012/PH/MWSUG-2012-PH02.pdf" ext-link-type="uri">https://mwsug.org/proceedings/2012/PH/MWSUG-2012-PH02.pdf</ext-link> [accessed 18 June 2024]</comment>.</mixed-citation></ref><ref id="bib16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schubart</surname> &#160;<given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Schilling</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Schaefer</surname> &#160;<given-names>E</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Use of prescription opioid and other drugs among a cohort of persons with Ehlers&#8211;Danlos syndrome: a retrospective study</article-title>. <source>Am J Med Genet A</source> &#160;<year>2019</year>;<volume>179</volume>:<fpage>397</fpage>&#8211;<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.61031</pub-id><pub-id pub-id-type="pmid">30624009</pub-id></mixed-citation></ref><ref id="bib17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ba</surname> &#160;<given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Risher</surname> &#160;<given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Ssentongo</surname> &#160;<given-names>P</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Human immunodeficiency virus (HIV) treatment with antiretroviral therapy mitigates the high risk of mental health disorders associated with HIV infection in the US population</article-title>. <source>Open Forum Infect Dis</source> &#160;<year>2023</year>;<volume>10</volume>:<fpage>ofad555</fpage>. <pub-id pub-id-type="doi">10.1093/ofid/ofad555</pub-id><pub-id pub-id-type="pmid">38033986</pub-id><pub-id pub-id-type="pmcid">PMC10686352</pub-id></mixed-citation></ref><ref id="bib18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chinchilli</surname> &#160;<given-names>VM</given-names></string-name>, <string-name name-style="western"><surname>Ssentongo</surname> &#160;<given-names>P</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Association of long COVID with mental health disorders: a retrospective cohort study using real-world data from the USA</article-title>. <source>BMJ Open</source> &#160;<year>2024</year>;<volume>14</volume>:<fpage>e079267</fpage>. <pub-id pub-id-type="doi">10.1136/bmjopen-2023-079267</pub-id><pub-id pub-id-type="pmcid">PMC10840030</pub-id><pub-id pub-id-type="pmid">38309763</pub-id></mixed-citation></ref><ref id="bib19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Austin</surname> &#160;<given-names>PC</given-names></string-name></person-group>. <article-title>An introduction to propensity score methods for reducing the effects of confounding in observational studies</article-title>. <source>Multivar Behav Res</source> &#160;<year>2011</year>;<volume>46</volume>:<fpage>399</fpage>&#8211;<lpage>424</lpage>. <pub-id pub-id-type="doi">10.1080/00273171.2011.568786</pub-id><pub-id pub-id-type="pmcid">PMC3144483</pub-id><pub-id pub-id-type="pmid">21818162</pub-id></mixed-citation></ref><ref id="bib20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Elm</surname> &#160;<given-names>Ev</given-names></string-name>, <string-name name-style="western"><surname>Altman</surname> &#160;<given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Egger</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies</article-title>. <source>BMJ</source> &#160;<year>2007</year>;<volume>335</volume>:<fpage>806</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.39335.541782.AD</pub-id><pub-id pub-id-type="pmid">17947786</pub-id><pub-id pub-id-type="pmcid">PMC2034723</pub-id></mixed-citation></ref><ref id="bib21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Elixhauser</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Steiner</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Harris</surname> &#160;<given-names>DR</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Comorbidity measures for use with administrative data</article-title>. <source>Med Care</source> &#160;<year>1998</year>;<volume>36</volume>:<fpage>8</fpage>&#8211;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1097/00005650-199801000-00004</pub-id><pub-id pub-id-type="pmid">9431328</pub-id></mixed-citation></ref><ref id="bib22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Garland</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Olafson</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ramsey</surname> &#160;<given-names>CD</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Epidemiology of critically ill patients in intensive care units: a population-based observational study</article-title>. <source>Crit Care</source> &#160;<year>2013</year>;<volume>17</volume>:<fpage>R212</fpage>. <pub-id pub-id-type="doi">10.1186/cc13026</pub-id><pub-id pub-id-type="pmid">24079640</pub-id><pub-id pub-id-type="pmcid">PMC4056438</pub-id></mixed-citation></ref><ref id="bib23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>House</surname> &#160;<given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Wanner</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sarnak</surname> &#160;<given-names>MJ</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference</article-title>. <source>Kidney Int</source> &#160;<year>2019</year>;<volume>95</volume>:<fpage>1304</fpage>&#8211;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.kint.2019.02.022</pub-id><pub-id pub-id-type="pmid">31053387</pub-id></mixed-citation></ref><ref id="bib24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Townsend</surname> &#160;<given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Taler</surname> &#160;<given-names>SJ</given-names></string-name></person-group>. <article-title>Management of hypertension in chronic kidney disease</article-title>. <source>Nat Rev Nephrol</source> &#160;<year>2015</year>;<volume>11</volume>:<fpage>555</fpage>&#8211;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1038/nrneph.2015.114</pub-id><pub-id pub-id-type="pmid">26215512</pub-id></mixed-citation></ref><ref id="bib25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thomas</surname> &#160;<given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Brownlee</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Susztak</surname> &#160;<given-names>K</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Diabetic kidney disease</article-title>. <source>Nat Rev Dis Primer</source> &#160;<year>2015</year>;<volume>1</volume>:<fpage>15018</fpage>. <pub-id pub-id-type="doi">10.1038/nrdp.2015.18</pub-id><pub-id pub-id-type="pmcid">PMC7724636</pub-id><pub-id pub-id-type="pmid">27188921</pub-id></mixed-citation></ref><ref id="bib26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>C&#226;mara</surname> &#160;<given-names>NOS</given-names></string-name>, <string-name name-style="western"><surname>Iseki</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kramer</surname> &#160;<given-names>H</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Kidney disease and obesity: epidemiology, mechanisms and treatment</article-title>. <source>Nat Rev Nephrol</source> &#160;<year>2017</year>;<volume>13</volume>:<fpage>181</fpage>&#8211;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1038/nrneph.2016.191</pub-id><pub-id pub-id-type="pmid">28090083</pub-id></mixed-citation></ref><ref id="bib27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Turakhia</surname> &#160;<given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Blankestijn</surname> &#160;<given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Carrero</surname> &#160;<given-names>JJ</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference</article-title>. <source>Eur Heart J</source> &#160;<year>2018</year>;<volume>39</volume>:<fpage>2314</fpage>&#8211;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehy060</pub-id><pub-id pub-id-type="pmid">29522134</pub-id><pub-id pub-id-type="pmcid">PMC6012907</pub-id></mixed-citation></ref><ref id="bib28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname> &#160;<given-names>CY</given-names></string-name>, <string-name name-style="western"><surname>Liao</surname> &#160;<given-names>KM</given-names></string-name></person-group>. <article-title>Chronic obstructive pulmonary disease is associated with risk of chronic kidney disease: a nationwide case-cohort study</article-title>. <source>Sci Rep</source> &#160;<year>2016</year>;<volume>6</volume>:<fpage>25855</fpage>. <pub-id pub-id-type="doi">10.1038/srep25855</pub-id><pub-id pub-id-type="pmid">27166152</pub-id><pub-id pub-id-type="pmcid">PMC4863146</pub-id></mixed-citation></ref><ref id="bib29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kreisman</surname> &#160;<given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Hennessey</surname> &#160;<given-names>JV</given-names></string-name></person-group>. <article-title>Consistent reversible elevations of serum creatinine levels in severe hypothyroidism</article-title>. <source>Arch Intern Med</source> &#160;<year>1999</year>;<volume>159</volume>:<fpage>79</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1001/archinte.159.1.79</pub-id><pub-id pub-id-type="pmid">9892334</pub-id></mixed-citation></ref><ref id="bib30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stengel</surname> &#160;<given-names>B</given-names></string-name></person-group>. <article-title>Chronic kidney disease and cancer: a troubling connection</article-title>. <source>J Nephrol</source> &#160;<year>2010</year>;<volume>23</volume>:<fpage>253</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">20349418</pub-id><pub-id pub-id-type="pmcid">PMC4823382</pub-id></mixed-citation></ref><ref id="bib31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shirazian</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Grant</surname> &#160;<given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Aina</surname> &#160;<given-names>O</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Depression in chronic kidney disease and end-stage renal disease: similarities and differences in diagnosis, epidemiology, and management</article-title>. <source>Kidney Int Rep</source> &#160;<year>2016</year>;<volume>2</volume>:<fpage>94</fpage>&#8211;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1016/j.ekir.2016.09.005</pub-id><pub-id pub-id-type="pmid">29318209</pub-id><pub-id pub-id-type="pmcid">PMC5720531</pub-id></mixed-citation></ref><ref id="bib32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ghahramani</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Razjouyan</surname> &#160;<given-names>H</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>The association between proton pump inhibitor use and risk of post-hospitalization acute kidney injury: a multicenter prospective matched cohort study</article-title>. <source>BMC Nephrol</source> &#160;<year>2023</year>;<volume>24</volume>:<fpage>150</fpage>. <pub-id pub-id-type="doi">10.1186/s12882-023-03211-4</pub-id><pub-id pub-id-type="pmid">37237361</pub-id><pub-id pub-id-type="pmcid">PMC10224298</pub-id></mixed-citation></ref><ref id="bib33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Austin</surname> &#160;<given-names>PC</given-names></string-name></person-group>. <article-title>Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research</article-title>. <source>Commun Stat Simul Comput</source> &#160;<year>2009</year>;<volume>38</volume>:<fpage>1228</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1080/03610910902859574</pub-id></mixed-citation></ref><ref id="bib34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fine</surname> &#160;<given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Gray</surname> &#160;<given-names>RJ</given-names></string-name></person-group>. <article-title>A proportional hazards model for the subdistribution of a competing risk</article-title>. <source>J Am Stat Assoc</source> &#160;<year>1999</year>;<volume>94</volume>:<fpage>496</fpage>&#8211;<lpage>509</lpage>. <pub-id pub-id-type="doi">10.1080/01621459.1999.10474144</pub-id></mixed-citation></ref><ref id="bib35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Inker</surname> &#160;<given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Eneanya</surname> &#160;<given-names>ND</given-names></string-name>, <string-name name-style="western"><surname>Coresh</surname> &#160;<given-names>J</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>New creatinine- and cystatin C-based equations to estimate GFR without race</article-title>. <source>N Engl J Med</source> &#160;<year>2021</year>;<volume>385</volume>:<fpage>1737</fpage>&#8211;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2102953</pub-id><pub-id pub-id-type="pmid">34554658</pub-id><pub-id pub-id-type="pmcid">PMC8822996</pub-id></mixed-citation></ref><ref id="bib36"><label>36.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>Agency for Healthcare Research and Quality</collab></person-group>. <article-title>LOINC</article-title>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://digital.ahrq.gov/loinc" ext-link-type="uri">https://digital.ahrq.gov/loinc</ext-link> [accessed 8 April 2024]</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15360280802537332</pub-id><pub-id pub-id-type="pmid">21923316</pub-id></mixed-citation></ref><ref id="bib37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gleiss</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Oberbauer</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Heinze</surname> &#160;<given-names>G</given-names></string-name></person-group>. <article-title>An unjustified benefit: immortal time bias in the analysis of time-dependent events</article-title>. <source>Transpl Int</source> &#160;<year>2018</year>;<volume>31</volume>:<fpage>125</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1111/tri.13081</pub-id><pub-id pub-id-type="pmid">29024071</pub-id></mixed-citation></ref><ref id="bib38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Agarwal</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Moshier</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ru</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Immortal time bias in observational studies of time-to-event outcomes</article-title>. <source>Cancer Control</source> &#160;<year>2018</year>;<volume>25</volume>:<fpage>1073274818789355</fpage>. <pub-id pub-id-type="doi">10.1177/1073274818789355</pub-id><pub-id pub-id-type="pmid">30021466</pub-id><pub-id pub-id-type="pmcid">PMC6053873</pub-id></mixed-citation></ref><ref id="bib39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fisher</surname> &#160;<given-names>LD</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname> &#160;<given-names>DY</given-names></string-name></person-group>. <article-title>Time-dependent covariates in the Cox proportional-hazards regression model</article-title>. <source>Annu Rev Public Health</source> &#160;<year>1999</year>;<volume>20</volume>:<fpage>145</fpage>&#8211;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.publhealth.20.1.145</pub-id><pub-id pub-id-type="pmid">10352854</pub-id></mixed-citation></ref><ref id="bib40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lund</surname> &#160;<given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Richardson</surname> &#160;<given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>St&#252;rmer</surname> &#160;<given-names>T</given-names></string-name></person-group>. <article-title>The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application</article-title>. <source>Curr Epidemiol Rep</source> &#160;<year>2015</year>;<volume>2</volume>:<fpage>221</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s40471-015-0053-5</pub-id><pub-id pub-id-type="pmid">26954351</pub-id><pub-id pub-id-type="pmcid">PMC4778958</pub-id></mixed-citation></ref><ref id="bib41"><label>41.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Goyal</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cusick</surname> &#160;<given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Thielemier</surname> &#160;<given-names>B</given-names></string-name></person-group>. <source>ACE inhibitors</source>. <publisher-loc>Treasure Island, FL</publisher-loc>: <publisher-name>StatPearls Publishing</publisher-name>, <year>2023</year>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK430896/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK430896/</ext-link>. [accessed 7 February 2024]</comment>.<pub-id pub-id-type="pmid">28613646</pub-id></mixed-citation></ref><ref id="bib42"><label>42.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>McKeever</surname> &#160;<given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Hamilton</surname> &#160;<given-names>RJ</given-names></string-name></person-group>. <article-title>Calcium channel blockers</article-title>. <publisher-loc>Treasure Island, FL</publisher-loc>: <publisher-name>StatPearls Publishing</publisher-name>, <year>2022</year>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK482473/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK482473/</ext-link> [accessed 8 December 2023]</comment>.<pub-id pub-id-type="pmid">29494080</pub-id></mixed-citation></ref><ref id="bib43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ostchega</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname> &#160;<given-names>DT</given-names></string-name></person-group>. <article-title>Hypertension prevalence among adults aged 18 and over: united States, 2017&#8211;2018</article-title>. <source>NCHS Data Brief</source> &#160;<year>2020</year>;<volume>364</volume>:<fpage>1</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">32487290</pub-id></mixed-citation></ref><ref id="bib44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brar</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname> &#160;<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>James</surname> &#160;<given-names>MT</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with outcomes after acute kidney injury</article-title>. <source>JAMA Intern Med</source> &#160;<year>2018</year>;<volume>178</volume>:<fpage>1681</fpage>&#8211;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1001/jamainternmed.2018.4749</pub-id><pub-id pub-id-type="pmid">30422153</pub-id><pub-id pub-id-type="pmcid">PMC6583606</pub-id></mixed-citation></ref><ref id="bib45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pan</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vasbinder</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname> &#160;<given-names>E</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and outcomes in patients hospitalized for COVID-19</article-title>. <source>J Am Heart Assoc</source> &#160;<year>2021</year>;<volume>10</volume>:<fpage>e023535</fpage>. <pub-id pub-id-type="doi">10.1161/JAHA.121.023535</pub-id><pub-id pub-id-type="pmid">34889102</pub-id><pub-id pub-id-type="pmcid">PMC9075226</pub-id></mixed-citation></ref><ref id="bib46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lopes</surname> &#160;<given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Macedo</surname> &#160;<given-names>AVS</given-names></string-name>, <string-name name-style="western"><surname>de Barros</surname> &#160;<given-names>E</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial</article-title>. <source>JAMA</source> &#160;<year>2021</year>;<volume>325</volume>:<fpage>254</fpage>&#8211;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.25864</pub-id><pub-id pub-id-type="pmid">33464336</pub-id><pub-id pub-id-type="pmcid">PMC7816106</pub-id></mixed-citation></ref><ref id="bib47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname> &#160;<given-names>J</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19</article-title>. <source>Circ Res</source> &#160;<year>2020</year>;<volume>126</volume>:<fpage>1671</fpage>&#8211;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.317134</pub-id><pub-id pub-id-type="pmid">32302265</pub-id><pub-id pub-id-type="pmcid">PMC7265882</pub-id></mixed-citation></ref><ref id="bib48"><label>48.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>European Society of Cardiology</collab></person-group>. <article-title>Position Statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers</article-title>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang" ext-link-type="uri">https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang</ext-link> [accessed 31 October 2023]</comment>.</mixed-citation></ref><ref id="bib49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>American College of Cardiology</collab></person-group>. <article-title>HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19</article-title>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19" ext-link-type="uri">https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19</ext-link> [accessed 31 October 2023]</comment>.</mixed-citation></ref><ref id="bib50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname> &#160;<given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Muntner</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Chertow</surname> &#160;<given-names>GM</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Acute kidney injury and mortality in hospitalized patients</article-title>. <source>Am J Nephrol</source> &#160;<year>2012</year>;<volume>35</volume>:<fpage>349</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1159/000337487</pub-id><pub-id pub-id-type="pmid">22473149</pub-id><pub-id pub-id-type="pmcid">PMC3362180</pub-id></mixed-citation></ref><ref id="bib51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rewa</surname> &#160;<given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Bagshaw</surname> &#160;<given-names>SM</given-names></string-name></person-group>. <article-title>Acute kidney injury&#8212;epidemiology, outcomes and economics</article-title>. <source>Nat Rev Nephrol</source> &#160;<year>2014</year>;<volume>10</volume>:<fpage>193</fpage>&#8211;<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1038/nrneph.2013.282</pub-id><pub-id pub-id-type="pmid">24445744</pub-id></mixed-citation></ref><ref id="bib52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McKee</surname> &#160;<given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Castelli</surname> &#160;<given-names>WP</given-names></string-name>, <string-name name-style="western"><surname>McNamara</surname> &#160;<given-names>PM</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>The natural history of congestive heart failure: the Framingham Study</article-title>. <source>N Engl J Med</source> &#160;<year>1971</year>;<volume>285</volume>:<fpage>1441</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM197112232852601</pub-id><pub-id pub-id-type="pmid">5122894</pub-id></mixed-citation></ref><ref id="bib53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morgan</surname> &#160;<given-names>CJ</given-names></string-name></person-group>. <article-title>Reducing bias using propensity score matching</article-title>. <source>J Nucl Cardiol</source> &#160;<year>2018</year>;<volume>25</volume>:<fpage>404</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s12350-017-1012-y</pub-id><pub-id pub-id-type="pmid">28776312</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>